FibroGen(FGEN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 FibroGen Reports Third Quarter 2024 Financial Results • Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025 • Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025 • Third quarter net revenue growth of 15% year over year, driv ...